LUGPA Series
LUGPA Virtual Crossfire Discussion and Debate Series
Presentations
nmCRPC Updates: Focus on QoL and AE data updates
Speakers: Sukumar Ethirajan, Medical DirectorNeal D. Shore, MD, FACS, Medical Director, CPIAaron Berger, MD, Vice President and Director of Advanced Prostate Cancer Duration: 60 minutes
Presented on: March 5, 2021
*This session is not eligible for AMA PRA Category 1 CreditsTM
Advanced Prostate Cancer: Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice
Speakers: Scott Sellinger, MD, FACS, President, Advanced Urology InstituteNeal D. Shore, MD, FACS, Medical Director, CPI Duration: 60 minutes
Presented on: July 27, 2021
*This session is not eligible for AMA PRA Category 1 CreditsTM
A case-based discussion: Genomic testing for increased confidence in management of localized prostate cancer
Speakers: Andrew Stephenson, MD, Section Chief and Director, Urologic OncologySoroush Rais-Bahrami, MD, Associate Professor, Urology and RadiologyNeal D. Shore, MD, FACS, Medical Director, CPI Duration: 60 minutes
Presented on: October 1, 2021
*This session is not eligible for AMA PRA Category 1 CreditsTM
Translating New Data into nmCRPC Treatment Decisions
Speakers: Neal D. Shore, MD, FACS, Medical Director, CPITian Zhang, MD, MHS, Associate Professor, Division of Hematology and OncologyBenjamin Lowentritt, MD, FACS, Vice president of Physician Services Duration: 60 minutes
Presented on: October 12, 2021
*This session is not eligible for AMA PRA Category 1 CreditsTM
Genomic testing and mpMRI: A case-based discussion on a multimodal approach to management of localized prostate cancer
Speakers: Robert Reiter, MD, Professor, Urology, Molecular BiologyBrian Helfand, MD, PhD Duration: 60 minutes
Presented on: December 8, 2021
*This session is not eligible for AMA PRA Category 1 CreditsTM
Private Equity (PE): Fad or Future?
Speakers: Deepak Kapoor, MD, Market PresidentScot Davis, CEOJonathan Henderson, MD, CEONeal D. Shore, MD, FACS, Medical Director, CPI Duration: 60 minutes
Presented on: December 9, 2020
*This session is not eligible for AMA PRA Category 1 CreditsTM
Speakers
Sukumar Ethirajan
Sukumar Ethirajan
Medical Director
Sukumar Ethirajan, MD, has over 25 years of clinical and scientific experience and has co-authored numerous scientific publications. He founded Dr.E.T.’s Concierge Care, LLC in Overland Park, Kansas and serves on multiple boards, including the Center for Practical Bioethics and the NCCN State Oncology Society Forum. Dr Ethirajan earned his MBBS (medical) degree at the University of Madras – Stanley Medical College in India and completed post-graduate training at Boston University, Harvard University, University of California – Los Angeles, and University of Minnesota.Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Medical Director, CPI
Neal Shore, MD, is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare,US. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer and the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr. Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology-Oncology. Also, he’s a Fellow of the American College of Surgeons.Session Appearances
Second-line Therapy and Beyond for Progressive UC
Redefining the ‘Best’ Treatment Option for Patients with UTUC
Refining the First-Line and Maintenance Therapy Approach for Advanced/Metastatic UC
Translating New Data into nmCRPC Treatment Decisions
Advanced Prostate Cancer: Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice
A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options
Aaron Berger, MD
Aaron Berger, MD
Vice President and Director of Advanced Prostate Cancer
Aaron D. Berger, MD, is vice president and director of Advanced Prostate Cancer with Associated Urological Specialists in the Southwest suburbs of Chicago. He earned his Bachelor of Science degree at the University of Wisconsin – Madison and attended medical school at the David Geffen School of Medicine at the University of California – Los Angeles. Dr Berger went on to complete his residency in Urology at New York University’s Langone Medical Center and his fellowship at the University of California – San Francisco.
Scott Sellinger, MD, FACS
Scott Sellinger, MD, FACS
President, Advanced Urology Institute
Scott Sellinger, MD, FACS, is president of the Advanced Urology Institute (AUI) in Tallahassee, Florida, chairs the Advanced Prostate Cancer (APC) Committee, and oversees seven APC clinics within AUI. In addition, he has served on the board of directors for the Large Urology Group Practice Association (LUGPA) for the past six years. Dr Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on these subjects during the past several years. He is also interested in large group practice development and management.
Andrew Stephenson, MD
Andrew Stephenson, MD
Section Chief and Director, Urologic Oncology
Soroush Rais-Bahrami, MD
Soroush Rais-Bahrami, MD
Associate Professor, Urology and Radiology
.jpg)
Tian Zhang, MD, MHS
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Tian Zhang, MD, MHS, received her medical degree from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School and completed post-graduate training at Duke University, where she remained on faculty for 6 years. Currently, Dr. Zhang is an Adjunct Associate Professor within the Division of Medical Oncology and Medicine in the Department of Medicine at Duke University School of Medicine. Also, she is a member of the Duke Cancer Institute as a medical oncologist. In addition, Dr. Zhang is an active clinical researcher focused on improving novel therapies and biomarkers for patients with prostate, kidney, and urothelial cancers. Some projects include circulating tumor cells as biomarkers and aiding patients to make informed decisions on cancer treatment options.
Benjamin Lowentritt, MD, FACS
Benjamin Lowentritt, MD, FACS
Vice president of Physician Services
Benjamin Lowentritt, MD, FACS, serves as vice president of Physician Services and director of Prostate Cancer Services for United Urology Group in Baltimore, Maryland. He also serves as the medical director of the Comprehensive Prostate Cancer Care Program at Chesapeake Urology. Dr Lowentritt has been at the forefront of robotic urology procedures and was the first surgeon in Maryland to perform robot assisted surgery for bladder cancer. He has authored articles on a variety of urologic topics. Dr Lowentritt has served as past president of the Mid-Atlantic Section of the American Urological Association. He serves on the board of directors for MedChi and the Maryland State Medical. Dr Lowentritt has been recognized as a Top Doctor in multiple publications.Robert Reiter, MD
Robert Reiter, MD
Professor, Urology, Molecular Biology
Brian Helfand, MD, PhD
Brian Helfand, MD, PhD
Deepak Kapoor, MD
Scot Davis
Jonathan Henderson, MD
Jonathan Henderson, MD
CEO
Jonathan Henderson, MD, is the CEO of Regional Urology, LLC in Shreveport, Louisiana. He received his MD at Louisiana State University Medical Center (LSUMC) in Shreveport, and he completed his internship and residency in urology at LSUMC Hospital. Dr Henderson spent the following 6 years in practice in Alabama, specializing in treating disorders of the female bladder and laparoscopy. During this time, he served as a representative of Alabama to the Southeastern Section of the American Urology Association, and was an assistant clinical professor of urology at the University of Alabama. Dr Henderson is a member of the American Urologic Association, Shreveport Medical Society, Louisiana State Medical Society, Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society.
.jpg)
